Fujifilm has expanded its breast imaging solutions with the launch Tomosynthesis Biopsy option for the ASPIRE Cristalle mammography system. The new option will calculate 3D coordinates of a suspicious lesions in the breast, and will allow radiologists to complete a biopsy of suspicious areas and inform of the diagnosis and care plan. It will also allow clinicians to be able enhance diagnostic care for patient by targeting a lesion that was previously undetectable on full digital mammography.
‘Fujifilm is committed to empowering clinicians to detect breast cancer and help save lives through early intervention” comments Rick Banner, Senior Director of Marketing, FUJIFILM Medical Systems U.S.A., Inc “The availability of Tomosynthesis Biopsy enhances our women’s health imaging portfolio and will assist clinicians in providing enhanced patient care.”
“Fujifilm releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System“
The result of the combination is a low dose and fast acquisition of images for all breast types. Patients will also notice an improvement in the level of comfort offered during procedures, thanks to the paddle design providing a gentle compression that’s designed to adapt to the patients curves.
Tomosynthesis Biopsy will be presented by Fujifilm’s representatives at the Association for Medical Imaging Management in Denver Colorado.